Table 3.
Features associated with sarcopenia, obesity and sarcopenic obesity
| Sarcopenia | Obesity | Sarcopenic obesity | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient characteristics | No (n = 49) | Yes (n = 31) | P | No (n = 48) | Yes (n = 32) | P | No (n = 62) | Yes (n = 18) | P |
| Median age (years) | 65 (28–80) | 67 (34–82) | 0.277 | 65 (28–80) | 66 (37–82) | 0.180 | 65 (28–80) | 72 (43–82) | 0.029 |
| Sex, number of men (%) | 33 (67.3) | 18 (58.1) | 0.400 | 30 (62.5) | 21 (65.6) | 0.776 | 36 (58.1) | 15 (83.3) | 0.050 |
| BMI (kg/m2) | 26.0 (19.6–46.4) | 24.2 (18.7–33.0) | 0.016 | 23.6 (18.7–32.1) | 28.6 (21.8–46.4) | <0.001 | 24.3 (18.7–46.4– | 26.6 (21.8–33.0) | 0.324 |
| Child–Pugh Grade A | 83.7 | 79.3 | 0.627 | 85.4 | 76.7 | 0.327 | 85.5 | 68.8 | 0.120 |
| Child–Pugh Grade B | 16.3 | 20.7 | 0.627 | 14.6 | 23.3 | 0.327 | 14.5 | 31.3 | 0.120 |
| MELD score | 7 (6–20) | 7 (6–19) | 0.648 | 7 (6–20) | 9 (6–19) | 0.015 | 7 (6–20) | 8 (6–19) | 0.093 |
| Liver volume | |||||||||
| Total liver volume (mL) | 1762 (1111–3883) | 1578 (1067–3290) | 0.127 | 1592 (1067–3883) | 1831 (1142–3290) | 0.084 | 1656 (1067–3883) | 1768 (1142–3290) | 0.637 |
| Tumour volume (mL) | 28 (0–2002) | 63 (0–709) | 0.659 | 50 (0–2002) | 72 (0–709) | 0.481 | 50 (0–2002) | 72 (0–709) | 0.627 |
| Non-tumour TLV (mL) | 1678 (1052–2852) | 1518 (869–2581) | 0.215 | 1533 (869–2852) | 1694 (1116–2685) | 0.079 | 1562 (869–2852) | 1638 (1116–2581) | 0.541 |
| Non-tumour TLV–body weight ratio (%) | 2.02 (1.31–3.22) | 2.28 (1.34–3.19) | 0.181 | 2.24 (1.43–3.22) | 1.97 (1.31–3.19) | 0.062 | 2.06 (1.31–3.22) | 2.16 (1.34–3.19) | 1.000 |
| Liver function | |||||||||
| LiMAx value (µg/kg/h) | 324 (125–594) | 327 (95–684) | 0.917 | 358 (96–684) | 295 (95–508) | 0.018 | 333 (96–684) | 313 (95–490) | 0.378 |
| LiMAx/ntTLV (µg/kg/h/mL) | 0.19 (0.06–0.47) | 0.21 (0.07–0.44) | 0.707 | 0.22 (0.06–0.47) | 0.17 (0.07–0.32) | 0.004 | 0.20 (0.06–0.47) | 0.18 (0.07–0.32) | 0.246 |
| Laboratory testing (normal) | |||||||||
| Bilirubin (mg/dL) (<1.2) | 0.6 (0.2–14.3) | 0.8 (0.3–5.6) | 0.356 | 0.6 (0.2–4.3) | 0.8 (0.3–14.3) | 0.140 | 0.6 (0.2–14.3) | 0.8 (0.3–5.6) | 0.162 |
| ALT (U/L) (<50) | 35 (15–358) | 32 (15–234) | 0.615 | 32 (15–234) | 39 (15–358) | 0.516 | 36 (15–358) | 29 (15–121) | 0.341 |
| AST (U/L) (<38) | 45 (14–224) | 46 (15–150) | 0.311 | 45 (19–211) | 49 (14–224) | 0.965 | 46 (14–224) | 40 (15–150) | 0.313 |
| INR (ratio) | 1.06 (0.82–1.24) | 1.04 (0.90–1.45) | 0.700 | 1.03 (0.82–1.19) | 1.06 (0.90–1.45) | 0.038 | 1.04 (0.82–1.24) | 1.05 (0.90–1.45) | 0.190 |
| C-reactive protein (mg/L) (<5) | 9 (1–172) | 11 (1–187) | 0.107 | 8 (1–95) | 19 (1–187) | 0.007 | 9 (1–172) | 14 (1–187) | 0.034 |
| Creatinine (mg/dL) (0.6–1.1) | 0.9 (0.6–3.8) | 0.8 (0.5–2.3) | 0.130 | 0.8 (0.5–3.8) | 0.9 (0.5–2.3) | 0.623 | 0.8 (0.5–3.8) | 0.9 (0.5–2.3) | 0.373 |
| Albumin (g/L) (35–52) | 36.7 (24.3–45.8) | 35.1 (19.5–45.8) | 0.138 | 36.3 (22.6–45.8) | 35.7 (19.5–43.1) | 0.693 | 36.6 (22.6–45.8) | 35.1 (19.5–41.7) | 0.313 |
BMI, body mass index; ntTLV, non-tumour total liver volume.